WO2005078070A1 - 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 - Google Patents
胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 Download PDFInfo
- Publication number
- WO2005078070A1 WO2005078070A1 PCT/JP2005/002027 JP2005002027W WO2005078070A1 WO 2005078070 A1 WO2005078070 A1 WO 2005078070A1 JP 2005002027 W JP2005002027 W JP 2005002027W WO 2005078070 A1 WO2005078070 A1 WO 2005078070A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- cell
- embryonic stem
- feeder
- medium
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/30—Organic components
- C12N2500/44—Thiols, e.g. mercaptoethanol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/113—Acidic fibroblast growth factor (aFGF, FGF-1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1323—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
Definitions
- the present invention relates to a medium for producing a feeder cell used for culturing embryonic stem cells including human embryonic stem cells, a method for producing a feeder cell using the medium, and a method for producing the same. And a feeder cell for embryonic stem cells obtained by the method.
- Embryonic stem cells are undivided cells derived from the inner cell mass of a blastocyst, have a variety that allows differentiation into all tissues, and include cell culture, tissue transplantation, and drug discovery. It is expected to find applications in research and gene therapy. Furthermore, it is also known that cloned embryonic stem cells obtained by transplanting adult somatic cell nuclei are induced. In recent years, techniques for inducing embryonic stem cells into various tissues including neural tissues have been reported. Tissues derived from embryonic stem cells are genetically equivalent tissues without immune exclusion. It is expected to be used for transplantation medicine and gene therapy.
- embryonic stem cells have been extended to primates including small experimental animals, humans, and it has been reported that the isolation of rhesus monkey embryonic stem cells and the separation of embryonic stem cells from human in vitro fertilized eggs have been reported. You.
- Suemori et al. Succeeded in producing new embryonic stem cells from microinjected fertilized eggs of power quizal, which are useful for preclinical studies and widely used in medical research, and have obtained pluripotent cells. It demonstrated that sex was maintained for a long time, and further demonstrated that dominant nerves could be induced from this force-quiz monkey embryonic stem cells.
- Embryonic stem cells including human embryonic stem cells as described above have been conventionally co-cultured with feeder cells to promote their growth.
- embryonic stem cells of primates including humans cannot be maintained in an undifferentiated state when cultured using serum! Therefore, culture in a serum-free medium has been studied (see Patent Document 1).
- embryonic stem cells cannot be maintained only by culturing in a serum-free medium, and the effect of serum cannot be maintained.
- Co-culture with feeder cells has been essential to replace some of them.
- human feeder cells derived from human embryonic stem cells and mouse-derived feeder cells were used as the feeder cells because, for example, fibroblasts prepared from mouse embryos were used to stop proliferation by mitomycin C or irradiation.
- Co-culture with zirconium could cause zoonotic diseases. Since tissues derived from human embryonic stem cells are expected to be used as materials for transplantation medicine and gene therapy, it is desirable to eliminate as much as possible the risk of zoonotic infections.
- Non-Patent Document 1 human embryonic fibroblasts, adult oviduct epithelial cells (Non-Patent Document 1), human neonatal foreskin-derived fibroblasts (Non-Patent Documents 2, 3), adult epidermal lines A method using fibroblasts (Non-patent document 4) and human bone marrow cells (Non-patent document 5) as a single feeder cell has been reported.
- Serum such as fetal calf serum (FBS) is used as a medium for producing these human-derived feeder cells, and unknown pathogens such as unknown infectious diseases and prions are transmitted from this serum. There is a risk of being done.
- FBS fetal calf serum
- Patent Document 1 International Publication No. 98Z30679 pamphlet
- Non-Patent Document 1 Nat.Biotechnol. 20: 933-936 (2002)
- Non-Patent Document 2 Biol. Reprod. 68: 2150-2156 (2003)
- Non-Patent Document 3 Hum. Reprod. 18: 1404-1409 (2003)
- Non-Patent Document 4 Stem Cells. 21: 546-556 (2003)
- Non-Patent Document 5 Stem Cells. 21: 131-142 (2003)
- An object of the present invention is to efficiently establish feeder cells used for culturing embryonic stem cells including human embryonic stem cells from materials derived from a limited number of donors, and to reduce the risk of infection.
- An object of the present invention is to provide a feeder-one cell preparation medium for embryonic stem cells (hereinafter referred to as a "feeder-one cell preparation medium") that can be cultured in a state. Further, a method for producing a feeder cell which is relatively safe even when co-cultured with embryonic stem cells, and a method for producing a feeder cell obtained thereby. To provide.
- a fetus that can be a feeder cell of embryonic stem cells by using a feeder cell preparation medium containing at least serum albumin and insulin in a basal medium.
- a feeder cell preparation medium containing at least serum albumin and insulin in a basal medium.
- the present inventors have found that a cell population containing one cell type can be stably expanded, and have completed the present invention.
- the present invention consists of the following.
- a feeder-one-cell preparation medium for embryonic stem cells comprising at least one selected from Ham F12, Mediuml99, RPMI1640, RITC 80-7, MCDB104, MCDB105, MCDB153, MCDB201 and MCDB202.
- cell adhesion factor is at least one selected from collagen, gelatin, fibronectin, vitronectin, laminin, polylysine, polyortin and polyethyleneiminka.
- the medium according to the above item 4 wherein the cell growth factor is at least one selected from fibroblast growth factor and epithelial cell growth factor.
- the cell adhesion factor is at least one selected from collagen, gelatin, fibronectin, vitronectin, laminin, polylysine, polyortin and polyethyleneiminka.
- a feeder for embryonic stem cells obtained by the production method according to any one of items 6 to 9 of the preceding item.
- the feeder single cell preparation medium of the present invention can establish relatively safe feeder cells even when co-cultured with embryonic stem cells including human embryonic stem cells, and enables long-term culture.
- Materials for feeder cells include, for example, fetal epidermal fibroblasts, fetal myofibroblasts, fetal lung fibroblasts, fetal epithelial cells, fetal endothelial cells, adult epidermal fibroblasts, adult lung fibroblasts, adult epithelial cells, It is useful to be able to perform long-term culture because it is derived from limited donors such as adult endothelial cells.
- the present invention can provide an embryonic stem cell having a low risk of diseases and the like.
- FIG. 1 is a view showing a 10-day colony ( ⁇ 40) of force-quiz monkey embryonic stem cells cultured with the feeder cell prepared in Example 2.
- FIG. 2 is a view showing colonies (100-fold) on day 4 after subculture of force-quigus monkey embryonic stem cells cultured with a feeder cell prepared in Example 2.
- FIG. 3 is a view showing the proliferation of force-quigus monkey embryonic stem cells cultured by the feeder cell prepared in Example 2.
- FIG. 4 is a diagram showing an immunostained image (100 ⁇ ) of SSEA-4 of a colony on day 4 after subculture of a force-quiz monkey embryonic stem cell cultured by a feeder cell prepared in Example 2 is there
- FIG. 5 is a view showing a 10-day colony (40-fold) of force-quiz monkey embryonic stem cells cultured by a feeder cell prepared in Example 3.
- FIG. 6 is a diagram showing colonies (100-fold) on day 4 after subculture of force-quigus monkey embryonic stem cells cultured with a feeder cell prepared in Example 3.
- FIG. 7 is a view showing the proliferation of force-quiz monkey embryonic stem cells cultured by the feeder cell prepared in Example 3.
- FIG. 8 is a diagram showing the proliferation of MRC-5 when cultured in combination with a gelatin coat and a feeder-one-cell preparation medium (B) in Example 4. The PDL at the start of the culture and the PDL at the end of the culture, for which the ability to measure the number of cells at the time of subsequent subculturing was also calculated, are shown.
- FIG. 9 is a diagram showing the proliferation of MRC-5 when cultured in combination with a collagen coat and a feeder-one-cell preparation medium (B) in Example 5. The PDL at the start of the culture and the PDL at the end of the culture calculated from the cell number measurement during the subsequent subculture are described.
- a 1: 1 mixed medium of DMEM and Ham F12, which can be used for serum-free culture of embryonic stem cells, can improve the nutrient value of the medium and the survival rate in co-culture with embryonic stem cells after the preparation of feeder cells More suitable.
- composition of the basal medium used in the present invention is based on the sources described in Table 1.
- the feeder-cell preparation medium used in the present invention contains serum albumin and insulin as essential components. This medium may further contain other components. However, other components that contain unknown components such as fetal bovine serum (FBS) or contaminants and that have a high risk of infectious diseases are inappropriate.
- FBS fetal bovine serum
- Other components include those that are not contained in the basal medium or those that are contained in the basal medium but whose amounts are not sufficient. Specific examples include cell adhesion factors, cell growth factors, metal-containing proteins such as transferrin, other polypeptide-proteins, amino acids, and vitamins. These components are mixed with a basic medium to produce a feeder-cell preparation medium.
- a medium called a feeder-cell preparation medium can also be produced by blending a commercially available serum substitute or the like with the above-mentioned basic medium. This serum replacement usually contains serum albumin and insulin, and also contains other components as described above. Therefore, a serum substitute can be blended with the basal medium in an amount such that serum albumin and insulin become the desired amounts. Examples of the serum substitute include a serum substitute described in Patent Document 1 described above.
- the feeder-cell preparation medium of the present invention contains a cell adhesion factor as the above-mentioned other components. Further, it is preferable that a cell growth factor is contained. Further, it is preferable that a metal-containing protein such as transferrin is contained.
- the cell adhesion factor is preferably at least one selected from collagen, gelatin, fibronectin, vitronectin, laminin, polylysine, polyortin and polyethyleneimine.Particularly, collagen, gelatin, fibronectin, Vitronek Chin and the like are preferred.
- the cell growth factor is preferably at least one selected from fibroblast growth factor (FGF) and epidermal growth factor (EGF).
- the feeder-cell preparation medium in the present invention is essential to contain serum albumin at a ratio of 2gZL-50gZL and insulin at a ratio of lmgZL-100mgZL.
- a more preferred amount of serum albumin is 4gZL-25gZL, and the amount of insulin is 5mgZL-30mgZL.
- the cell adhesion factor is contained in an amount of about 0.3mgZL-50mgZL.
- the cell growth factor is preferably contained in the feeder-cell preparation medium at a ratio of 0.01 ⁇ gZL—100 gZL.
- fibroblast growth factor is contained at 0.1 g / z gZL—10 gZL.
- the preferred epidermal growth factor is 0.
- metal-containing proteins such as transferrin are contained at a ratio of lmgZL-50mgZL.
- Cells that can be used to establish a feeder cell for embryonic stem cells of the present invention include, for example, fetal epidermal fibroblasts, fetal myofibroblasts, fetal lung fibroblasts, fetal epithelial cells, fetal endothelium Cells, adult epidermal fibroblasts, adult lung fibroblasts, adult epithelial cells, adult skin cells At least one cell type can be selected.
- the cell population containing the selected cell type is placed in a culture vessel containing the feeder-cell preparation medium of the present invention under a condition of 3% to 10% CO, 35 ° C to 40 ° C for 1 day.
- the production method including the steps of cell growth and cell growth arrest, safe feeder cells for embryonic stem cells that are grown under serum-free culture and have almost no animal-derived infection are produced. be able to.
- the cell culture container can be coated in advance with a cell adhesion factor.
- a feeder cell can be produced in large quantities by dividing the cultured cells 20 times or more on average.
- Feeder-one cell preparation medium (A) Composition:
- RI RITC80-7 medium supplemented with 5 g / L of serum albumin (BSA), 10 ⁇ g / L of EGF, lmg / L of insulin, and lmg / L of cortisol in the mouth
- the cultured MRC-5 was cultured for 2-3 hours using a feeder-one cell preparation medium (A) containing mitomycin C (MMC) at a final concentration of 10 ⁇ g / ml, Cell division was inactivated. Thereafter, the feeder-cell preparation medium (A) containing MMC was removed, and the cells were washed three times with a phosphate buffer solution (PBS). The washed cells were peeled off from the culture dish by trypsin treatment (0.25 w / v% trypsin, 1 mM EDTA), and the number of cells was counted. As a result, about 5.5 X 10 6 feeder cells could be obtained.
- A feeder-one cell preparation medium
- MMC mitomycin C
- PBS phosphate buffer solution
- MRC-5 which was obtained from the same cell bank as in Example 1, was suspended in the following feeder-cell formation medium (B) to a cell count of 3 ⁇ 4.l ⁇ 10 5 cells, and gelatin-coated. The cells were subcultured four times on the culture dish, and cultured to 53.47 PDL. Then, the cultured MRC-5 was cultured for 2-3 hours using a feeder-cell formation medium (B) containing MMC at a final concentration of 10 / zg / ml to inactivate cell division. Thereafter, the feeder-cell preparation medium containing MMC was removed, and the cells were washed three times with PBS to prepare feeder-cells. The feeder cells were seeded on a gelatin-coated 60 mm diameter petri dish at a rate of about 4 ⁇ 10 5 viable cells per cell and allowed to settle.
- B feeder-cell formation medium
- Feeder-one cell preparation medium (B) Composition:
- the cultured force-quiz monkey embryonic stem cell colonies were dissociated from the petri dish by trypsin treatment (0.25 w / v% trypsin).
- the cells in a part of the petri dish were reseeded into a petri dish containing a new feeder cell, and then cultured under the same conditions for 4 days.
- the cells in the remaining petri dish were detached from the petri dish, and the number of cells was counted.
- the morphology of the viable monkey embryonic stem cell colony was the same as that cultivated in a single feeder cell derived from mouse fetal fibroblasts at the time of V and at the end of the passage and at the end of the culture. Yes (Figs. 1 and 2), and the force-Cuis monkey embryonic stem cells proliferated (Fig. 3).
- the immunostaining at the end of the culture showed fluorescence by SSEA-4, one of the primate embryonic stem cell markers (Fig. 4), confirming that the colony was a primate embryonic stem cell colony. It was revealed.
- embryonic stem cells can be cultured using a feeder cell from MRC-5 prepared by the method of the present invention.
- MRC-5 supplied from the same cell bank as in Example 1 was suspended in a feeder-cell preparation medium (B) so that the cell viability was 3 ⁇ 40.4 ⁇ 10 6 cells, and a collagen-coated culture chamber was suspended. The cells were subcultured four times and cultured to 53.68 PDL. Next, the cultured MRC5 was cultured for 2-3 hours in a feeder-one-cell preparation medium (B) containing MMC at a final concentration of 10 ⁇ g Zml to inactivate cell division. Then, the feeder-cell preparation medium containing MMC was removed, and the cells were washed three times with PBS to prepare feeder-cells.
- B feeder-cell preparation medium
- MRC-5 which was obtained from the same cell bank as in Example 1, was suspended in a feeder-cell preparation medium (B) so as to be 2.1 ⁇ 10 5 cells, and grown on a gelatin-coated culture dish. Subculture was repeated until it became worse, and the growth limit by serum-free culture was examined. As a result, it was confirmed that fibroblasts that could be a feeder cell with the medium of the present invention could grow from 41.77 PDL up to 4 passages and could divide to about 53 PDL (FIG. 8). This suggests that it is possible to produce a single feeder cell in an amount equivalent to the power of one cell line.
- MRC-5 donated from the same cell bank as in Example 1 was suspended in a feeder-one cell preparation medium (B) so as to be 2.1 ⁇ 10 5 cells, and the growth was poor on a collagen-coated culture dish. Subculture was repeated to the extent possible, and the growth limit due to serum-free culture was examined. As a result, fibroblasts, which can become feeder cells with the medium of the present invention, can grow up to 7 passages even with 41.77 PDL power, and the fibroblasts reach the limit of finite dividing cells V, up to about 60 PDL. It was confirmed that the cells could be split (Fig. 9).
- a human normal diploid lung fibroblast cell line obtained from a cell bank cultured to 28.76 PDL in MEM medium supplemented with 10% v / v FBS was added to a feeder-one cell preparation medium (B). The cells were suspended at 1.8 ⁇ 10 5 cells and cultured on a collagen-coated culture dish to 35.51 PDL with two subcultures interposed therebetween.
- TIG-3 was cultured for 2-3 hours in a feeder-cell preparation medium (B) containing MMC at a final concentration of 10 ⁇ g Zml to inactivate cell division. Then remove the medium containing MMC The cells were washed three times with PBS. The cells after washing were removed from the culture dish by trypsin treatment (0.25 w / v% trypsin, 1 mM EDTA), and the number of cells was counted. As a result, about 2.1 X 10 7 cells per feeder were obtained.
- MRC-5 supplied from the same cell bank as in Example 1 was added to a medium for human primary fibroblasts (hereinafter referred to as “FGM”) modified with MCDB202 and supplemented with 1 ⁇ g of FGF / 5 mg / L of insulin and not containing serum albumin.
- FGM human primary fibroblasts
- the cells were suspended at 2.2 ⁇ 10 5 cells using Cambrex, and cultured on a gelatin-coated culture dish with one subculture. However, after the passage, cell growth stopped, and MMC treatment was not possible, and it was difficult to produce feeder cells.
- MRC-5 obtained from the same cell bank as in Example 1 was suspended using FGM to 2.2 x 10 5 cells, and cultured on a collagen-coated culture dish with one subculture. did. As in Comparative Example 1, the growth of the cells was stopped after the passage, and the cells could not be treated with MMC, and it was difficult to prepare one feeder cell.
- one feeder cell used for culturing embryonic stem cells including human embryonic stem cells can be produced in a serum-free medium with a low risk of animal-derived infection.
- long-term cultivation is possible by combining with cell adhesion factors such as gelatin and collagen, so that materials from a limited number of donors can be used to the utmost and feeder cell
- the risk of source contamination from changing donors is also very low.
- the present invention since the present invention was confirmed to be applicable to a plurality of cell lines by Examples, the present invention can also be used for producing individual feeder cells suitable for embryonic stem cells derived from various types of animals. .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Gynecology & Obstetrics (AREA)
- Rheumatology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005517970A JPWO2005078070A1 (ja) | 2004-02-13 | 2005-02-10 | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 |
US10/588,804 US20080085554A1 (en) | 2004-02-13 | 2005-02-10 | Culture Medium for Culturing Feeder Cells for Embryonic Stem Cells Culture and the Prepared Feeder Cells |
CA002555021A CA2555021A1 (en) | 2004-02-13 | 2005-02-10 | Medium for preparing feeder cells for embryonic stem cells and feeder cells |
AU2005212041A AU2005212041A1 (en) | 2004-02-13 | 2005-02-10 | Medium for preparing feeder cells for embryonic stem cells and feeder cells |
EP05710079A EP1715033A4 (en) | 2004-02-13 | 2005-02-10 | MEANS FOR PREPARING NOURISHED CELLS FOR EMBRYONIC STEM CELLS AND NOURISHED CELLS |
IL177245A IL177245A0 (en) | 2004-02-13 | 2006-08-02 | The culture medium for culturing feeder cells for embryonic stem cells culture and the prepared feeder cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004036845 | 2004-02-13 | ||
JP2004-036845 | 2004-02-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005078070A1 true WO2005078070A1 (ja) | 2005-08-25 |
Family
ID=34857731
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/002027 WO2005078070A1 (ja) | 2004-02-13 | 2005-02-10 | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20080085554A1 (ja) |
EP (1) | EP1715033A4 (ja) |
JP (1) | JPWO2005078070A1 (ja) |
KR (1) | KR20060114381A (ja) |
CN (1) | CN1914313A (ja) |
AU (1) | AU2005212041A1 (ja) |
CA (1) | CA2555021A1 (ja) |
IL (1) | IL177245A0 (ja) |
TW (1) | TW200526782A (ja) |
WO (1) | WO2005078070A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2948381B1 (fr) | 2009-07-24 | 2013-07-12 | Oncobiotek | Procede d'obtention de myofibroblastes. |
WO2015103792A1 (zh) * | 2014-01-13 | 2015-07-16 | 深圳市汉科生物工程有限公司 | 保藏淋巴细胞体外培养增效剂的方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH078273A (ja) * | 1993-06-14 | 1995-01-13 | Kurabo Ind Ltd | 接着性動物細胞の無血清培養法 |
JP2001508302A (ja) * | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
WO2002029012A1 (en) * | 2000-10-03 | 2002-04-11 | University Of North Carolina | Processes for clonal growth of hepatic progenitor cells |
JP2003009854A (ja) * | 2001-04-09 | 2003-01-14 | Kyowa Hakko Kogyo Co Ltd | エンブリオイドボディ形成方法及びその用途 |
JP2003525625A (ja) * | 2000-03-09 | 2003-09-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 霊長類の胚幹細胞の無血清培養 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4565784A (en) * | 1981-01-26 | 1986-01-21 | Trustees Of Boston University | Hydrogels capable of supporting cell growth |
US5108923A (en) * | 1986-04-25 | 1992-04-28 | Collaborative Research, Inc. | Bioadhesives for cell and tissue adhesion |
US4973466A (en) * | 1988-06-21 | 1990-11-27 | Chiron Ophthalmics, Inc. | Wound-healing dressings and methods |
DE60040826D1 (de) * | 1999-11-26 | 2009-01-02 | Menicon Co Ltd | Verfahren zur Kultivierung von Zellen |
KR100865664B1 (ko) * | 2000-06-14 | 2008-10-29 | 비스타겐 인코포레이티드 | 간 줄기 세포를 사용하는 독성 타이핑 |
AU2002213259A1 (en) * | 2000-10-13 | 2002-04-22 | Hyseq, Inc. | Egf motif protein, egfl6 materials and methods |
ATE347695T1 (de) * | 2001-06-07 | 2006-12-15 | Chemocentryx Inc | Zellwanderungsassay |
US20040023322A1 (en) * | 2002-08-01 | 2004-02-05 | Goodheart Clyde R. | Method of producing non-recombinant BMP-2 and use thereof |
WO2004094615A2 (en) * | 2003-04-23 | 2004-11-04 | The Texas A & M University System | Prokaryotic collagen-like proteins and uses thereof |
-
2005
- 2005-02-10 EP EP05710079A patent/EP1715033A4/en not_active Withdrawn
- 2005-02-10 WO PCT/JP2005/002027 patent/WO2005078070A1/ja active Application Filing
- 2005-02-10 US US10/588,804 patent/US20080085554A1/en not_active Abandoned
- 2005-02-10 CA CA002555021A patent/CA2555021A1/en not_active Abandoned
- 2005-02-10 AU AU2005212041A patent/AU2005212041A1/en not_active Abandoned
- 2005-02-10 CN CNA2005800037931A patent/CN1914313A/zh active Pending
- 2005-02-10 JP JP2005517970A patent/JPWO2005078070A1/ja active Pending
- 2005-02-10 KR KR1020067018578A patent/KR20060114381A/ko not_active Application Discontinuation
- 2005-02-14 TW TW094104137A patent/TW200526782A/zh unknown
-
2006
- 2006-08-02 IL IL177245A patent/IL177245A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH078273A (ja) * | 1993-06-14 | 1995-01-13 | Kurabo Ind Ltd | 接着性動物細胞の無血清培養法 |
JP2001508302A (ja) * | 1997-01-10 | 2001-06-26 | ライフ テクノロジーズ,インコーポレイテッド | 胚性幹細胞血清置換 |
JP2003525625A (ja) * | 2000-03-09 | 2003-09-02 | ウィスコンシン アラムニ リサーチ ファンデーション | 霊長類の胚幹細胞の無血清培養 |
WO2002029012A1 (en) * | 2000-10-03 | 2002-04-11 | University Of North Carolina | Processes for clonal growth of hepatic progenitor cells |
JP2003009854A (ja) * | 2001-04-09 | 2003-01-14 | Kyowa Hakko Kogyo Co Ltd | エンブリオイドボディ形成方法及びその用途 |
Also Published As
Publication number | Publication date |
---|---|
IL177245A0 (en) | 2006-12-10 |
CA2555021A1 (en) | 2005-08-25 |
EP1715033A4 (en) | 2008-06-11 |
EP1715033A1 (en) | 2006-10-25 |
US20080085554A1 (en) | 2008-04-10 |
TW200526782A (en) | 2005-08-16 |
KR20060114381A (ko) | 2006-11-06 |
JPWO2005078070A1 (ja) | 2007-10-18 |
AU2005212041A1 (en) | 2005-08-25 |
CN1914313A (zh) | 2007-02-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5227318B2 (ja) | 細胞増殖培地 | |
JP6662777B2 (ja) | 人工心筋(ehm)を産生するための方法 | |
JP6148429B2 (ja) | ヒト多能性幹細胞の培養方法 | |
JP5612338B2 (ja) | 無血清条件下で初代細胞を培養する方法及びウイルスを増幅させる方法 | |
JP6581655B2 (ja) | 多能性幹細胞由来ケラチノサイトの生成およびケラチノサイト培養の維持 | |
Kidwai et al. | Differentiation of human embryonic stem cells into clinically amenable keratinocytes in an autogenic environment | |
JP2013143968A (ja) | 幹細胞及び胎児由来の心筋細胞及び予定心筋細胞の精製方法 | |
JPWO2011111787A1 (ja) | 間葉系幹細胞を含む細胞製剤及びその製造方法 | |
JP2016521541A (ja) | 合成メッセンジャーrnaによるヒト人工多能性幹細胞のフィーダーフリー誘導 | |
JP6744084B2 (ja) | 幹細胞由来の分化細胞用培地、幹細胞からの分化細胞の製造及び該分化細胞を含む細胞医薬組成物の製造のための方法 | |
Rungsiwiwut et al. | Human umbilical cord blood-derived serum for culturing the supportive feeder cells of human pluripotent stem cell lines | |
JP5067765B2 (ja) | 卵膜由来細胞の細胞外マトリクスを用いた多能性幹細胞の培養方法 | |
CN108795842B (zh) | 一种3D悬浮诱导iPS细胞生成自体黑素细胞的方法及应用 | |
WO2005078070A1 (ja) | 胚性幹細胞用フィーダー細胞作成培地およびフィーダー細胞 | |
KR101753596B1 (ko) | 바이러스 대량 생산용 신규 세포주 및 이의 제작 방법 | |
JP2007000077A (ja) | 付着性動物細胞の無血清培養方法及び付着性動物細胞の無血清培養用培地 | |
CN107236703B (zh) | 一种饲养层细胞、培养方法及应用 | |
TW200540270A (en) | Medium for feeder-free differentiation and feeder-free differentiation method from primate embryonic stem cell | |
JP2022540579A (ja) | cP1Pまたはその薬学的に許容可能な塩を有効成分として含む幹細胞増殖促進用組成物 | |
JP2016073323A (ja) | ヒト多能性幹細胞の培養方法 | |
KR100683199B1 (ko) | 신경전구세포를 콜린성 신경세포로 분화시키는 방법 및그에 사용되는 배지 | |
TWI698526B (zh) | 利用合成之信使rna進行之人類誘導型多能幹細胞之無餵養細胞衍化(derivation) | |
WO2017082295A1 (ja) | 軟骨組織塊及びその製造方法、並びに幹細胞から軟骨組織塊を誘導するための培地 | |
WO2023037544A1 (ja) | 多能性幹細胞の製造方法 | |
Chakrabarty et al. | iPSC-based disease modeling and prospective immune therapy for COVID-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 4398/DELNP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580003793.1 Country of ref document: CN Ref document number: 2555021 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 177245 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005710079 Country of ref document: EP Ref document number: 2005517970 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005212041 Country of ref document: AU |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
ENP | Entry into the national phase |
Ref document number: 2005212041 Country of ref document: AU Date of ref document: 20050210 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2005212041 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067018578 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10588804 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2005710079 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067018578 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10588804 Country of ref document: US |